PFE trades at ~8.8x forward P/E with a 6.5% dividend yield, significantly cheaper than peers like MRK and JNJ. The market is hyper-focused on the COVID revenue drop and patent cliff, ignoring the $43B Seagen acquisition, cost cuts, and 2026 pipeline catalysts. PFE is a textbook value play with capped downside and enormous upside potential over the next 3-5 years, paying a safe dividend while you wait. The Seagen acquisition fails to deliver expected revenues, pipeline catalysts disappoint, or the patent cliff impact is worse than anticipated.
PFE
HIGH
Mar 16, 17:45
Key Points
['PFE at ~$26 is down nearly 60% from pandemic highs.', 'Forward P/E of ~8.8x is a massive discount to peers.', '6.5% dividend yield is safe and anchors the portfolio.', 'Seagen acquisition makes PFE an oncology powerhouse.', '2026 is a catalyst year with 20+ Phase 3 trials.']
March 16, 2026 at 17:45